Navigation Links
New target isolated for leukemia drug development
Date:2/11/2014

SAN ANTONIO (February 11, 2014) There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases. In a paper published today in Leukemia, a Nature journal, a UT Health Science Center researcher has pinpointed a protein that could play a key, previously unknown role in the development of pediatric AML promising new information in the quest to treat and cure childhood leukemias.

AML starts at the point when cells mature into different kinds of blood cells. In AML, the cancerous cells grow and proliferate in an abnormal way, and they fail to develop, or differentiate, into normal functioning white blood cells. Also, high levels of a protein called WTAP contribute to abnormal cell behavior, observed Sanjay Bansal, Ph.D., a researcher at the Greehey Children's Cancer Research Center at The University of Texas Health Science Center at San Antonio.

Dr. Bansal and his team, working with leukemia cells, used a laboratory technique to "knock down" WTAP expression in AML cells. What resulted was, in the research world, a resounding success.

"Knocking down this protein, WTAP, greatly suppressed proliferation and induced differentiation," said Hima Bansal, Ph.D., senior research associate at the Health Science Center and lead author of the paper. "It took care of both problems."

But they needed to understand how WTAP levels get so high in AML in the first place.

The researchers turned to another protein called Hsp90, a so-called "molecular chaperone" that helps stabilize more than 200 other proteins, known as Hsp90 "clients".

"When we suppressed Hsp90, we reduced WTAP," Dr. Bansal said. "So we have discovered two things: WTAP's role in AML and the mechanism underlying its overexpression."

Many of Hsp90's other client proteins are known targets in oncology, and "WTAP joins the list," Dr. Bansal said.

This discovery could open the door to more effective therapies for children and adults with newly diagnosed AML or for patients who have failed currently available treatments.


'/>"/>

Contact: Elizabeth Allen
allenea@uthscsa.edu
210-450-2020
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. Nanobubbles plus chemotherapy equals single-cell cancer targeting
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
7. Genetically modified corn affects its symbiotic relationship with non-target soil organisms
8. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
9. Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression
10. Key proteins newly discovered form and function may provide novel cancer treatment target
11. Scientists discover new inflammatory target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
Breaking Biology Technology: